The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Heart to Heart: Cardiovascular Disease in Autoimmune Conditions

Heart to Heart: Cardiovascular Disease in Autoimmune Conditions

December 2, 2021 • By Jason Liebowitz, MD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

ACR Convergence 2021—A key challenge faced by rheumatologists is not only managing the primary manifestations of systemic autoimmune diseases, but also anticipating, preventing and treating the comorbidities that are often seen in these conditions. During the ACR Convergence 2021 Review Course, Joan Bathon, MD, professor of medicine and chief of the Division of Rheumatology, Columbia University Medical Center, New York, discussed the cardiovascular manifestations of autoimmune disease.

You Might Also Like
  • Coronary Microvascular Dysfunction May Predict Heart Disease in Rheumatoid Arthritis
  • Autoimmune Inflammation Increases Risk of Heart Disease
  • Cardiovascular Disease Risk High in RA Patients
Also By This Author
  • Lessons from Master Clinicians: An Interview with Dr. Richard Brasington

Rheumatic Disease & Cardiovascular Risk

Joan Bathon, MD

Dr. Joan Bathon

Dr. Bathon began her lecture by noting several facts that many clinicians know all too well: Cardiovascular mortality is higher in patients with rheumatoid arthritis (RA) than in healthy, age-matched controls; clinical and subclinical cardiovascular disease is frequently seen in patients with RA, systemic lupus erythematosus and other rheumatic conditions; and patients with anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV) have an increased incidence of cardiovascular events even when compared with patients with chronic kidney disease.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Dr. Bathon noted that more severe and active rheumatic disease may further be associated with the risk of cardiovascular disease. In a study of 603 patients with rheumatoid arthritis, Maradit-Kremers et al. found that, even after controlling for traditional cardiovascular risk factors and comorbidities, patients with erythrocyte sedimentation rates of ≥60 mm/hr, the presence of rheumatoid arthritis-associated vasculitis and the presence of rheumatoid arthritis-associated lung disease had significantly higher risk of cardiovascular death compared with patients with rheumatoid arthritis without these features.1

In a separate study, Solomon et al. showed that hazard ratios for cardiovascular events in patients with rheumatoid arthritis correlate with disease activity, with patients with high disease activity having the highest risk of cardiovascular events and those patients in clinical remission demonstrating the lowest risk of such events.2

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Dr. Bathon said these and other studies raise several questions: Is vascular inflammation increased in patients with rheumatoid arthritis, and if so, does such inflammation predict progression of atherosclerosis and incidence of future cardiovascular events? Do disease-modifying anti-rheumatic drugs (DMARDs) reduce vascular inflammation, and, if that is true, is this the mechanism by which they (putatively) reduce cardiovascular events?

Anti-Inflammatory Therapy

On this note, Dr. Bathon referenced the CANTOS trial, which was the first randomized, controlled trial in the general population to provide proof of concept that anti-inflammatory therapy reduces cardiovascular event rates.3 In this study, Ridker et al. enrolled more than 10,000 patients with previous myocardial infarction (MI) and a high-sensitivity C-reactive protein level of ≥2 mg/L, and randomized patients to one of three doses of canakinumab, a therapeutic monoclonal antibody targeting interleukin-1β, or to placebo.

Pages: 1 2 3 | Single Page

Filed Under: ACR Convergence, Conditions, Meeting Reports, Rheumatoid Arthritis Tagged With: ACR Convergence 2021, ACR Convergence 2021 – RA, Cardiovascular disease

You Might Also Like:
  • Coronary Microvascular Dysfunction May Predict Heart Disease in Rheumatoid Arthritis
  • Autoimmune Inflammation Increases Risk of Heart Disease
  • Cardiovascular Disease Risk High in RA Patients
  • Galectin-3 May Be a Biomarker for Cardiovascular Disease in RA

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)